(Globes) Israeli biopharmaceutical cystic fibrosis treatment developer Splisense announced on May 13 that it has closed a $28.5 million financing round. The Jerusalem-based company is developing mRNA-altering therapies for cystic fibrosis (CF) and other genetic pulmonary diseases. "Currently available treatments focus on treating the symptoms of the disease," said SpliSense CEO Dr. Gili Hart. "Our technology addresses the underlying genetic cause, thereby offering, for the first time, hope of restoring adequate lung function to CF patients."
2021-05-21 00:00:00Full ArticleBACK Visit the Daily Alert Archive